Reset Pharma is focused on utilizing psilocybin-assisted therapy for treating people with cancer-related mental health problems including demoralization, anxiety and depression.
Reset Pharma
Resets’ primary focus is using psilocybin to treat cancer patients experiencing demoralization; a perceived lack of control, hopelessness and helplessness and an increased risk of suicide.
The company have acquired exclusive rights to the data from the team at NYU Langone Health exploring the potential of psychedelics for treating patients with life-threatening illnesses.
“Reset Pharma is developing novel, innovative treatments to restore the quality of life to patients with life-threatening cancer experiencing clinically relevant demoralization, anxiety and depression. Our lead program uses psilocybin, a promising novel treatment, to provide both rapid, and long-lasting relief in these patients”
News
Activities
B2B
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates